Meng Mingyao, Liu Ying, Wang Wenju, Wei Chuanyu, Liu Feifei, Du Zhiqin, Xie Yanhua, Tang Weiwei, Hou Zongliu, Li Qihan
Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical CollegeKunming 650118, China.
Yan'an Affiliated Hospital of Kunming Medical University, Yunnan Cell Biology and Clinical Translation Research Center, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan ProvinceKunming 650051, Yunnan, People's Republic of China.
Am J Transl Res. 2018 Jan 15;10(1):212-223. eCollection 2018.
To investigate the clinical efficacy and safety of umbilical cord mesenchymal stem cell (UCMSC) transplantation for treating multiple sclerosis (MS), the patients with MS were recruited and treated with UCMSC. The procedure of preparing UCMSC was in accordance with the standards formulated by the International Society for Cell Biology. Cell surface markers, multiple differentiation potential and safety of UCMSC for transplantation were detected. The number of cells in each infusion was 1 to 2×10 cells/kg. Patients were recruited in accordance with the standards of the International Mesenchymal Stem Cells Transplantation Study Group. After treatment, the clinical therapeutic effects including symptoms, vital signs, clinical attacks, magnetic resonance imaging (MRI), neurological function scores and adverse reactions such as fever, dizziness, and vascular irritation were monitored and evaluated. In addition, the regulatory effects of UCMSC on immune system of patients were also assessed. The results showed that the patients' symptoms were improved after UCMSC transplantation. No clinical attacks occurred during transplantation. MRI revealed a reduced number of foci and Expanded Disability Status Scale scores were decreased. Some of patients had adverse reactions after transplantation. These adverse effects were not serious and lasted short duration, thus no intervention was conducted and let it be eliminated by itself. The mRNA expression of CD86, IL-2, CTLA-4, and HLADRB1 in peripheral blood was significantly decreased after UCMSC transplantation ( < 0.05). Based on our present studies, UCMSCs would be considered as a safe and alternative option for treatment of MS.
为研究脐带间充质干细胞（UCMSC）移植治疗多发性硬化症（MS）的临床疗效和安全性，招募了MS患者并采用UCMSC进行治疗。UCMSC的制备过程符合国际细胞生物学学会制定的标准。检测了UCMSC的细胞表面标志物、多向分化潜能及移植安全性。每次输注的细胞数量为1至2×10⁶个细胞/千克。患者按照国际间充质干细胞移植研究组的标准招募。治疗后，监测并评估包括症状、生命体征、临床发作、磁共振成像（MRI）、神经功能评分以及发热、头晕和血管刺激等不良反应在内的临床治疗效果。此外，还评估了UCMSC对患者免疫系统的调节作用。结果显示，UCMSC移植后患者症状得到改善。移植过程中未发生临床发作。MRI显示病灶数量减少，扩展残疾状态量表评分降低。部分患者移植后出现不良反应。这些不良反应不严重且持续时间短，因此未进行干预，任其自行消除。UCMSC移植后外周血中CD86、IL-2、CTLA-4和HLADRB1的mRNA表达显著降低（P<0.05）。基于我们目前的研究，UCMSCs可被视为治疗MS的一种安全且可供选择的方法。
